Summarized by Masters of Longevity from Longevity Technology.
A Korean biotech is advancing TLY012, a peptide targeting scar-forming liver cells.
Key Takeaways
- TLY012 is a peptide targeting cells that build liver scar tissue.
- D&D Pharmatech plans first-in-human Phase 1 testing in 2027.
- Preclinical stage findings are not proof of human efficacy.
